【作者】 陆菊明;
【Author】 LU Ju-ming Department of Endocrinology,General Hospital of PLA,Beijing 100853,China
【机构】 解放军总医院内分泌科;
【摘要】 今年ADA年会上揭晓了甘精胰岛素初始干预转归研究(ORIGIN)结果,中国有22个中心,近500例病例参与其中,因此ORIGIN研究结果对于中国的糖尿病治疗也将产生一定的影响。ORIGIN研究是首项旨在将空腹血糖降到正常范围的大型随机对照研究,该研究发现,早期甘精胰岛素治疗与不良心血管预后无关;可带来长达近7年的血糖平稳控制;低血糖发生率低;可有效延缓糖尿病疾病进展。另外,长期甘精胰岛素治疗并不会增加肿瘤风险。 更多还原
【Abstract】 American Diabetes Association(ADA) announced the result of Outcome Reduction with an Initial Glargine Intervention(ORIGIN) in 2012.There were 22 centers and nearly 500 subjects in China involved in the study,so the results of ORIGIN will undoubtly contribute to the management of diabetes in China to a certain extent.The ORIGIN study is the first large-scale randomized controlled study in reducing the fasting blood glucose down to normal range.The ORIGIN study found that the early use of insulin ... 更多还原 【关键词】 糖尿病; 甘精胰岛素; ORIGIN研究; 【Key words】 diabetes mellitus; glargine; ORIGIN study;
【分类号】R587.1
中华医学之家:http://www.xinxi85.com
投稿信箱:zhyxzj85@163.com
联系电话:029--13309215487 主编QQ:693891972 |